Is Greenlight Biosciences Holdings Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: GRNA) stock is to Hold GRNA stock.
Out of 1 analyst, 0 (0%) are recommending GRNA as a Strong Buy, 0 (0%) are recommending GRNA as a Buy, 1 (100%) are recommending GRNA as a Hold, 0 (0%) are recommending GRNA as a Sell, and 0 (0%) are recommending GRNA as a Strong Sell.
According to 1 Wall Street analyst that have issued a 1 year GRNA price target, the average GRNA price target is $0.30, with the highest GRNA stock price forecast at $0.30 and the lowest GRNA stock price forecast at $0.30.
The Wall Street analyst predicted that Greenlight Biosciences Holdings's share price could reach $0.30 by May 31, 2024. The average Greenlight Biosciences Holdings stock price prediction forecasts a potential upside of 2.04% from the current GRNA share price of $0.29.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.